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The Triggering Receptors Expressed on Myeloid cells (TREM) are a family of cell-surface molecules that control
inflammation, bone homeostasis, neurological development and blood coagulation. TREM-1 and TREM-2, the
best-characterized receptors so far, play divergent roles in several infectious diseases. In the intestine, TREM-1 is
highly expressed by macrophages, contributing to inflammatory bowel disease (IBD) pathogenesis. Contrary to
current understanding, TREM-2 also promotes inflammation in IBD by fueling dendritic cell functions. This review
will focus specifically on recent insights into the role of TREM proteins in IBD development, and discuss
opportunities for novel treatment approaches.
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Inflammatory bowel diseases (IBD) refer to chronic in-
flammatory disorders affecting the gastrointestinal tract,
whose etiology is yet unknown. The main factors contrib-
uting to disease pathogenesis have recently been identified
and among these, the gut microbiota, which is dominated
by intestinal bacteria, is emerging as a key candidate for
the design of innovative therapeutic strategies. Bacterial
compounds are recognized by a variety of receptors, in-
cluding the well-known Toll-Like Receptor (TLRs). The
relationship between IBD pathogenesis and TLRs has been
extensively studied leading to the discovery of several
mechanisms and/or genetic alterations that drive intestinal
inflammation. A new family of cell-surface receptors has
recently emerged as a potential modulator of the inflam-
matory response. The Triggering Receptors Expressed on
Myeloid cells (TREM) control several cell processes, in-
cluding inflammation, bone homeostasis, neurological de-
velopment and coagulation.
In this review, we will provide an overview of TREM
gene clusters focusing on the expression of TREM family
members and their role in inflammation. We will then
analyze in detail both TREM-1 and TREM-2 signaling and* Correspondence: sdanese@hotmail.com
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their action. Recent insights on their activity in IBD patho-
genesis reinforce the opportunity to control TREM func-
tions as a new therapeutic approach.
TREM: a novel class of immune receptors
Innate inflammatory responses are essential for the body to
defend itself against pathogens. A fine-tuning of immune
reactivity is, however, crucial to prevent excessive inflam-
mation and ensuing tissue damage. Pathogen sensing is
guaranteed by pattern recognition receptors (PRRs), which
identify specific pathogens, activate innate immune re-
sponses and shape adaptive immunity. Recently, another
class of cell-surface receptors has been identified: Trigger-
ing Receptor Expressed on Myeloid cells (TREM). These
receptors are important regulators of the immune re-
sponse, due to their ability to either amplify or decrease
PRR-induced signals.
Human and mouse gene clusters
The identification of the first member of the TREM family,
TREM-1, was achieved through research on the overlap
between cDNA and the nucleotide sequence encoding for
the NKp44 polypeptide on the GeneBank EST database
[1]. This research led to the recognition of a novel gene
cluster comprising several activating receptors within theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Genua et al. Journal of Translational Medicine 2014, 12:293 Page 2 of 12
http://www.translational-medicine.com/content/12/1/293IgG superfamily. In addition, TREM-1’s open reading
frame (ORF) matched to one related sequence, referred to
as TREM-2 [1]. Subsequently, TREM-2 was also identified
and characterized in a murine macrophage cell line, and
compared to the human gene [2].
Currently, the human TREM gene cluster (Figure 1A) in-
cludes several other members, namely the TREM-like tran-
scripts −1, −2, -3, and −4 (TREML1, TREML2, TREML3
and TREML4). The murine gene cluster (Figure 1B) how-
ever did not include NKp44, but did contain genes encod-
ing for the plasmacytoid-dendritic cell Trem (pDC-Trem),
Treml −1, −2, −4 and −6, and Trem3. This latter gene was
found also in the human cluster as a non-transcriptionally
active pseudo-gene [3]. It is important to note that while
both the murine and human gene clusters cover many pu-
tative coding sequences (reviewed in [4], Figure 1), protein
products have been discovered and characterized only for
few genes, as discussed below.
TREM structural and functional properties
TREMs share common structural properties, including
the presence of a single extracellular immunoglobulin-like
domain of the V-type, a trans-membrane domain and a
short cytoplasmic tail (Figure 1). In particular, the trans-
membrane domain possesses negatively charged residues
that interact with the positively charged residues of theFigure 1 The TREM gene cluster in mice and humans. Schematic diagr
(A) and mice (B). Genes encoding TREM protein were drawn in orange, wh
proteins are shown below the corresponding genes. The DAP12 adaptor is
corresponding ITIM.DNAX Activating Protein of 12 kDa (DAP12), a trans-
membrane adaptor containing an immunoreceptor
tyrosine-based activation motif (ITAM). The TREM like
transcript −1 (TLT-1), whether of human or murine ori-
gin, instead contains an intracellular domain with an
immunoreceptor tyrosine-based inhibitory motif (ITIM)
in the cytoplasmic tail, directly controlling downstream
signaling [5]. Similarly, TLT-2 of murine origin contains
an ITIM, whereas human TLT-2 possesses a putative SH3
binding motif [4,6] (Figure 1).
The extracellular Ig-like domain is responsible for the
recognition and binding of molecules. Unfortunately,
data available in current literature does not address the
identification of neither TREM-1 nor TREM-2 endogen-
ous ligands. The first evidence of these ligands stems
from Gibot and Colleagues, who suggested the presence
of a TREM-1 ligand in the surface of neutrophils during
endotoxemia [7]. Subsequently, a TREM-1 ligand was
recognized in the surface of platelets, both in resting
condition and after thrombin activation [8]. Further-
more, recent studies by Derive and Colleagues suggested
that the endogenous ligand for TREM-1 competes with
a 17 aminoacid sequence obtained from the cleavage of
the extracellular domain of TLT-1 [9]. As for TREM-1,
TREM-2Fc/chimera stitched on the surface of bone
marrow-derived cells, suggesting the presence of a putativeam that compares the order of genes in the TREM clusters in humans
ereas TREM-like genes are depicted in red. Models of the encoded
also shown with its ITAM. TLT proteins are shown with the
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identified in the anionic residues present on the surface of
GRAM positive and negative bacteria [11]. Finally, Piccio
and Colleagues found that the astrocytoma cell line
HTB12 expresses a ligand for TREM-2 [12].
At present, the only fully characterized ligand is the
membrane protein B7-H3, a member of the B7 family,
which binds TLT-2. Interestingly, a different strategy was
used to identify TLT-2 ligands, by searching for homo-
logues of CD28 family members, known receptors of B7
proteins [13]. It will be useful to employ similar novel
bio-informatic strategies in future to pursue the identifi-
cation of TREM ligands, especially given their peculiar
ability to interact with a broad spectrum of stimuli, in-
stead of recognizing a specific pathogen.
An additional important feature of TREM proteins is
their release as soluble forms (sTREM). Soluble TREM
may in fact be generated by the alternative splicing of
mRNA, producing secreted receptor isoforms [14]. Other-
wise, sTREM may be produced by the cleavage of the
extracellular domain off the cell surface [15]. To date,
the predominant source of sTREM remains unknown;
however, DAP12-coupled (TREM-1 and TREM-2) and
non-DAP12-coupled (TLT-1) soluble receptors have been
identified in biological fluids of both animals and patients
with inflammatory and infectious disorders [16-19], sug-
gesting their importance as new biological markers. In
general, soluble forms of receptors, such as sTREM-1 and
sTREM-2, seem to negatively regulate TREM signaling
through neutralization of the respective ligands, acting as
decoy receptors [20,21].
In summary, the structural and functional features of
TREM proteins support their involvement in controlling
immune response.
Expression pattern and functions of TREM family
members
Cells of the myeloid lineage primarily express TREM
proteins [4,22,23], but TREM have further been detected
in other cell types, such as platelets [24], bronchial epi-
thelial cells [25], gastric epithelial cells [26], and hepatic
endothelial cells [27].
Among the putative genes, human TREM1, TREM2,
TREML1 and TREML2, together with their correspondent
murine versions, have all been shown to translate into
protein products [22]. Moreover, proteins encoded by the
murine genes Trem3 [3], pDC-Trem [28], and Treml4
[29] have also been detected.
TREM-1, which remains the most studied receptor
within its family, was initially identified in differentiated
monocytes and in circulating blood neutrophils [1]. Subse-
quently, TREM-1 was detected in macrophages of both al-
veolar [30], hepatic [27], and intestinal origin [31,32].
Recently, TREM-1 expression has also been reported inendothelial cells [27] and gastric epithelial cells [26]. While
TREM-1 is recognized as an amplifier of inflammation in
cells of myeloid origin, its expression and activities in
endothelial and epithelial cells require further study.
TREM-2 was instead first detected on human monocyte-
derived dendritic cells (DC) [2,33], following which its ex-
pression was revealed in osteoclast and microglia cells [34],
as well as in alveolar [35], hepatic [27] and intestinal mac-
rophages [36]. Similarly to TREM-1, TREM-2’s expression
was also detected in endothelial cells [27] although its
function in this cell type is not yet fully characterized. Con-
versely to TREM-1, TREM-2 expression and function have
been linked to anti-inflammatory activities, especially in
the central nervous system (CNS), where TREM-2 expres-
sion is required for the differentiation of myelinating oligo-
dendrocytes [37].
Among the other TREM family members, Trem-3 has
been detected in mouse macrophages, where it is up-
regulated after lipopolysaccharide (LPS) exposure [3].
Similarly, pDC-Trem has been detected in plasmacytoid
DCs of murine origin, after CpG stimulation [28]. Interest-
ingly, Treml4 has been recently studied on mouse splenic
DCs, revealing its importance in recognizing apoptotic
and necrotic cells [29]. Finally, TLT-1 was initially identi-
fied in human platelets and megakaryocytes [38], where it
counteracted TREM-1 function, whereas TLT-2 has been
located in B and T-cell lines of human origin, as well as in
murine neutrophils and macrophages [6].
While TREM-1 and TREM-2 have been extensively
studied and characterized in several pathological condi-
tions, reports regarding the expression and function of the
other TREM are just at the beginning. Therefore, add-
itional information is required to better understand the
relevance and the significance of these receptors both
under physiological conditions and in disease states.
The dual-face of TREM-1 and TREM-2 in inflammation
Despite the conventional view, which dictates that TREM-
1 is a pro-inflammatory mediator whereas TREM-2 mainly
dampens inflammatory responses, recent evidence has
shed light into the complex and multi-faceted role of these
receptors.
Initial findings established TREM-1 as an amplifier of
inflammatory responses in experimental sepsis [39].
During infection, receptor expression is modulated and
soluble TREM-1 is released [40,41]. In addition, recom-
binant TREM-1/Fc fusion proteins or antagonistic pep-
tides rescue mice from endotoxemia or polymicrobial
sepsis [42].
Despite the apparent detrimental effects of overstimula-
tion through TREM-1, its signaling may also be required
for protective anti-inflammatory responses. It has been
shown that a moderate dose of TREM-1 siRNA improves
mice survival during polymicrobial sepsis, whereas high-
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neutrophil respiratory bursts and increasing mortality
in mice [43]. In contrast to polymicrobial sepsis, full
TREM-1 silencing has been shown to play a protective
role in endotoxemia [43]. Mice treated with an agonistic
TREM-1 antibody and infected with S. pneumoniae exhib-
ited an enhanced induction of the early inflammatory re-
sponse. However, prolonged activation of TREM-1 did
promote the resolution of pneumonia, leading to an accel-
erated elimination of bacteria, and consequently improved
survival [44].
In agreement with these findings, TREM-1 has been
recently linked to trans-epithelial migration of neutro-
phils after infection with P. aeruginosa [45]. TREM-1/3
deficiency resulted in an unexpected increase of local
and systemic cytokine production. In fact, neutrophils
lacking TREM-1/3 retained unaltered bacterial killing,
via phagocytosis and chemotaxis; however, histological
examination of TREM-1/3-deficient lungs revealed de-
creased neutrophil infiltration of the airways [45].
Since results obtained to date on TREM-1’s function
in controlling microbial infection have proven contro-
versial, novel tools are required to unambiguously in-
vestigate its function. To this extent, two different
groups have recently generated TREM-1 deficient mice
[46,47], with Weber and Colleagues demonstrating that
TREM-1 genetic deletion ameliorates dextran sulfate
sodium (DSS)-induced colitis while it does not appear
to affect control of the infection by specific pathogens,
such as Leishmania Major, influenza virus and Legion-
ella pneumoniae, displaying however a reduced neutro-
phil infiltration [46]. TREM-1 KO mice have likewise
been studied in a model of Klebsiella pneumoniae liver
abscess (KPLA) [48]. Interesting, the absence of TREM-
1 increased K. pneumoniae dissemination, enhanced
liver and systemic inflammation, and reduced survival,
as a result of impaired bacterial clearance in the small
intestine [48]. We may thus conclude that TREM-1’s
function and activities may be dependent on the type of
infection.
TREM-2 regulates the differentiation of a broad range
of myeloid cells, including osteoclasts and oligodendro-
cytes. In fact, patients with Nasu-Hakola disease (NHD)
characterized by pre-senile dementia and bone cyst for-
mation, harbor loss-of-function mutations in the genes
encoding DAP12 and TREM-2 [49]. Both genetic lesions
lead to the development of an identical disease, resulting
from the failure of TREM-2 signaling due to a defect in
either TREM-2 itself or the associated DAP12 signaling
cascade.
The detrimental effect of TREM-2 abrogation in the
CNS is also supported by the study of the experimental
autoimmune encephalomyelitis (EAE), an animal model
for multiple sclerosis. TREM-2 expression is up-regulatedon microglia cells and infiltrating macrophages in both the
spinal cord and brain during inflammatory burst [12], and
myeloid cells transduced with TREM-2 dampen EAE in
mice, by migrating to the CNS and releasing anti-
inflammatory cytokines [50].
Contrary to current understanding, recent work by Correale
et al. [51] and Sieber et al. [52] provided evidence that, in
experimental models of gut inflammation and stroke, loss
of TREM-2 function leads to an attenuated inflammatory
reaction. The absence of TREM-2 in intestinal lamina-
propria DCs was likewise shown to lead to a reduced pro-
duction of pro-inflammatory cytokines and mitigation of
T-cell activation during experimental colitis [51]. Similarly,
genetic deletion of TREM-2 leads to a decreased produc-
tion of TNF-α, IL-1β and IL-6 after stroke, associated with
reduced microglia activation [52].
Further studies are needed to better elucidate the
functions and activities of TREM-1 and TREM-2, espe-
cially in regards to single-pathogen infection as com-
pared to a polymicrobial-driven disease. Evaluating the
signaling elicited by TREM-1 or by TREM-2 may repre-
sent a winning strategy to clarify their function.
The cell-type specificity of TREM-1 and TREM-2 elicited
signaling
Literature on TREM-1 signaling has been recently
reviewed [23]. Signaling cascades activated by the inter-
action between TREM-2 and DAP12 have been ad-
dressed by Paradowska-Gorycka and Jurkowska [53],
and readers are referred to those papers for a thorough
review of these issues.
The use of cross-linked antibodies or fusion proteins
has been the main strategy pursued to date to identify
intracellular mediators and signaling cascades, activated
either by TREM-1 or by TREM-2. In this work we will
systematically review the main intracellular mediators
and the principal outcomes directly linked to TREM-1
or TREM-2 activation, specifically focusing on the cell
types involved in these responses (Figure 2).
Neutrophils
Neutrophils are essential for phagocytosis and proteoly-
sis through which bacteria, cellular debris and particles
are removed and destroyed. Therefore, neutrophil func-
tion and activities are crucial during a poly-microbial
systemic infection, such as sepsis. Interestingly, TREM-1
is specifically enhanced in neutrophils during sepsis [1],
while TREM-2 expression was not detected in this spe-
cific cell type.
– Intracellular mediators
TREM-1 engagement was initially related to the
activation of the extracellular signal-related kinase
1/2 (ERK1/2), and phospholipase C-γ (PLC-γ) [1].
Figure 2 TREM-1 and TREM-2 signaling. Overview of the main intracellular mediators activated by TREM-1 (A) and TREM-2 (B), in order to elicit
downstream signaling. Depending on the cell-type involved, TREM-1 or TREM-2 ligation might activate different cytoplasmic adaptors, producing
different outcomes.
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clarified that TREM-1 is also able to couple with the
non-T cell activation linker (NTAL, also called linker
of activation in B cell, LAB). TREM-1/NTAL
interaction reduces ERK1/2 phosphorylation and
Ca2+ mobilization. The complex picture of TREM-1’s
signaling cascade includes the tyrosine-protein kinase
Lyn, the Proteinase Kinase B (AKT), and the Janus
Kinase-2 (JAK2). JAK2 activation ultimately leads to
the translocation of STAT5 and RelA, a subunit of
the nuclear factor-κB [55]. Finally, Haselmayer and
Colleagues showed that TREM-1 ligation activates the
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K),
and the mitogen-activated kinase p38MAPK [56].
– Outcomes
The first effect elicited by TREM-1 ligation is a
DAP-12 dependent Ca2+ influx [1]. This event is
followed by the activation of signaling cascades with
Jak/STATand NF-κΒ as main elements [55]; TREM-1
consecutively promotes the release of several
pro-inflammatory cytokines, such as IL-1β, IL-2, IL-6,
IL-8, IL-12p40, and TNF, as well as chemokines, such
as macrophage inflammatory protein (MIP)-1α
[54,57-59]. As a final outcome, TREM-1 activation
increases neutrophil degranulation and phagocytic
activity.
Monocyte/Macrophages
Macrophages are specialized immune cells, strategically
stationed as “sentinels” where microbial invasion oraccumulation of exogenous particles occurs. Under
pathological conditions, circulating monocytes are re-
cruited to the injured or inflamed tissues, where they dif-
ferentiate into specialized macrophages, such as Kupffer
cells in the liver, osteoclasts in the bone, and microglia
cells in the CNS. While we observed a specific expression
of TREM-1 in neutrophils, monocytes and macrophages
co-express TREM-1 and TREM-2. However, current lit-
erature has not explored the possible cross-talk between
the two receptors.
– Intracellular mediators
As for neutrophils, TREM-1 activation in mono-
cytes/macrophages leads to the activation of ERK1/2
and PI3K [1]. Liver macrophages have been also
studied after LPS stimulation, in the presence or
absence of the TREM-1/Fc fusion protein, confirming
that the downstream activation of PI3K and
p38MAPK is dependent on TREM-1 [27].
Interestingly, a recent work from Yuan and
Colleagues took advantage of the availability of
TREM-1 deficient macrophages and of TREM-1
over-expressing adenovirus, proving that TREM-1
signaling is involved in the activation of the
transcription factor early growth response protein
2 (Egr2) [60].
In parallel, TREM-2 signaling has been also evaluated
in macrophages, where it was found to be essential for
the activation of SYK, and involved downstream both
the small guanosine triphosphatases RAC1 and
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cytoskeleton rearrangement [61]. Moreover, a
recent study from Peng and Colleagues further
explored TREM-2 induced signaling in macrophages
and osteoclasts, clarifying that Ca2+ influx is also
mediated by the activation of PI3K, ERK1/2 and the
guanine nucleotide exchange factor Vav3; these
activities required the adaptor molecule DAP10
and were inhibited by the Src homology 2 (SH2)
domain-containing inositol phosphatase-1 (SHIP1)
[62]. Studies on osteoclastogenesis have proven that
TREM-2 is implicated in Ca2+-mediated activation
of the receptor activator of NF-κB (RANK), which
is required to promote downstream activation of
calcium/calmodulin-dependent protein kinase
(CaMK)II, MEK and ERK [63]. Finally, NTAL
engagement is also crucial in TREM-2 induced
signaling in macrophages, since it has been shown
to regulate monocyte-to-macrophages differentiation,
controlling subsequent anti-inflammatory
responses [64].
– Outcomes
A complete picture of the outcomes elicited by
TREM-1 or TREM-2 activation in monocyte/
macrophages is the subject of intense investigation.
The currently held view recognizes TREM-1 as a
skewed pro-inflammatory receptor, which augments
the release of cytokines, such as TNF, IL-6, IL-8 and
IL-1β [32]. Moreover, TREM-1 up-regulation has
been found in Tumor-Associated Macrophages
(TAM) isolated from patients with lung cancer [65].
Conversely, TREM-2 expression is necessary to
promote the differentiation of osteoclasts [34], as to
accelerate intestinal wound healing mediated by
macrophage polarization [36].
At present it remains unclear whether the
differences observed are due to a TREM-specific
recruitment of intracellular mediators, or to a
different synergism with other immune receptors,
such as TLRs. Moreover, recent insights have
underlined the importance of taking into account
the expression levels of other innate immune
receptors, and the complexity of the interaction
between the environment and those receptors,
especially in macrophages from different tissues [66].
DCs
DCs are professional antigen-presenting cells inter-
spersed within tissues, and are also in close contact with
the external environment, as such representing the link
between the innate and adaptive immune system. Inter-
estingly, TREM-1 and TREM-2 are both expressed by
DCs, although TREM-2 was the first to be recognized as
a central player in DC maturation and activation [33].– Intracellular mediators
While TREM-1 signaling has been widely studied
in neutrophils and macrophages, only one study
attempted to identify the effect of TREM-1
activation in mature DCs, clarifying that receptor
engagement led to the activation of ERK-1, Protein
Kinase B (AKT), and the transcription factor IκBα [67].
Conversely, TREM-2 was initially investigated
during DC maturation, and therefore analyses of
the intracellular mediators focused on these specific
cell-types. In particular, in monocyte-derived
DCs, TREM-2 ligation led to a rapid rise in the
intracellular level of Ca2+, followed by the activation
of Protein Tyrosin Kinases (PTKs), such as SYK, and
ERK1/2, without inducing IκBα/NF-κB or p38/
MAPK signaling pathways [33].
– Outcomes
The discovery that TREM-1 is also implicated in the
control of DC function is very recent, with Bosco
and Colleagues having identified TREM-1 as a
hypoxia-inducible gene [67]. Their work provided
evidence that TREM-1 engagement promotes the
up-regulation of T-cell co-stimulatory molecules
and homing chemokine receptors, typical of
mature DCs, as well as increasing the production
of pro-inflammatory stimuli, in turn provoking
intensified Th1/Th17-cell responses [68].
Similarly, TREM-2 activation in DCs leads to
enhanced expression of differentiation markers,
such as CCR7 [33]. However, controversial results
have been reported regarding the outcomes elicited
by TREM-2 activation. In fact, Ito and Colleagues
analyzed the effects of TREM-2 genetic deletion
on bone marrow-derived DCs, showing increased
release of TLR-induced pro-inflammatory cytokines
[69], in sharp contrast with TREM-2−/− intestinal DCs
which display lower production of pro-inflammatory
cytokines in response to TLR ligands [51].
TREM and PRRs liaison: effects on the elicited signaling
While studies conducted by cross-linking antibodies
have been instrumental in the identification of several
intracellular mediators, further research is necessary to
clarify the function of TREM, taking into account the
cell types involved and the interacting environment.
Among the factors that may contribute to TREM dif-
ferential responses, the expression pattern of PRRs may
be crucially involved in the cell type specificity of the in-
flammatory response. Remarkably, a comment from Julia
Klesney-Tait and Marco Colonna briefly revised the
interconnection between TREM-1 and TLR [70], analyz-
ing in detail the report from Ornatowska and Colleagues
[71]. Using pathway-specific microarray analyses, the au-
thors clarified that TREM-1’s synergism with TLR4 is
Genua et al. Journal of Translational Medicine 2014, 12:293 Page 7 of 12
http://www.translational-medicine.com/content/12/1/293dependent on the intracellular molecular adaptor en-
gaged [71]. In fact, in macrophages silenced for TREM-1
by RNA interfering, the signaling triggered by TLR4
through the engagement of TIR-domain-containing
adapter-inducing interferon-β (TRIF) is not affected. In
contrast, MyD88 and CD14 transcripts were decreased
following LPS stimulation in the setting of TREM-1 si-
lencing [71].
Similarly, TLR engagement has also been evaluated
in the context of DCs, providing evidence that TREM-
2-deficient BMDCs had increased TLR-induced maturation
and showed increased production of inflammatory cyto-
kines [69]. However, opposing results were obtained
when TREM-2’s deficiency effect was evaluated in intes-
tinal DCs [51].
In line with this data, the expression profile of selected
innate immune receptors has been outlined among the
various myeloid cell types [66], clarifying that a fine-tuned
crosstalk between such receptors is necessary to promote
anti-microbial defenses and avoid immune-related path-
ologies [66]. A far greater effort is therefore necessary to
unveil the expression and functional profile of TREM pro-
teins in the different subset of myeloid cells.
TREM-1 and TREM-2: friend or foe in IBD?
IBD refers to chronic inflammatory disorders that affect
the gastrointestinal tract [72]. There are two main clinical
forms of IBD, namely Crohn’s disease (CD) which can
affect any part of the intestine, and Ulcerative Colitis (UC)
which is restricted to the colonic mucosa [73]. Although
the pathogenesis of IBD is not yet fully understood, it is
becoming evident that these chronic disorders affect gen-
etically susceptible patients, leading to an increased expos-
ure of immune cells within the intestinal lamina-propria
to luminal bacteria [74].
Due to the peculiar activities of TREM-1 and TREM-2
in controlling bacterial infection, the functional role of
these two receptors has also been studied in IBD pa-
tients and in experimental models of colitis (Figure 3).
TREM-1 in IBD: could it be a therapeutic target in the near
future?
In both a T-cell transfer model of colitis in RAG2−/− mice
and in C57BL/6 mice with DSS-induced colitis, TREM-1
mRNA and protein have been shown to be significantly
up-regulated, a finding that preceded the appearance of
histological signs of the disease. Furthermore, administra-
tion of an antagonist TREM-1 peptide (LP17), even after
the establishment of colitis, decreased disease severity as
evaluated by the extent of colon shortening and by milder
alterations in colon histopathology [32]. LP17 treatment
also reduced TNF-α tissue levels. These findings uncov-
ered an important role for TREM-1 in the establishment
of IBD and suggest that targeting TREM-1 in the intestinecould be beneficial for patients suffering from IBD. While
only few TREM-1-expressing recently recruited blood
monocytes can be found in the normal colon, TREM-1
positive macrophages can be readily detected in the
lamina propria of patients with IBD, with no apparent
differences between active CD and UC [32]. TREM-1-
expressing macrophages in gut biopsies of patients with
IBD display a pro-inflammatory phenotype, consisting of
CD14 and CD89 co-expression. Therefore, TREM-1-
expressing macrophages acquire an aberrant phenotype in
IBD, and in vitro engagement of TREM-1 with a cross-
linking antibody resulted in enhanced production of TNF-
α, IL-6, IL-8, and monocyte chemotactic protein (MCP)-1
(Figure 3A) [32]. The origin of TREM-1-expressing mac-
rophages in IBD patients however remains a matter of de-
bate, since the concomitant expression of CD14 and
CD89 may suggest that the macrophages are exudative
cells recruited to the inflamed gut. In agreement with
these results, a recent work by Weber and Colleagues
indicated that, in the murine intestine, TREM-1 is preva-
lently expressed by a pro-inflammatory sub-population of
macrophages [75]. TREM-1 inhibition through the ad-
ministration of LP-17 has also been applied at the begin-
ning of following the induction of experimental colitis and
colitis associated carcinogenesis, revealing that the block-
age of TREM-1 activity exerts anti-inflammatory proper-
ties while also diminishing epithelial proliferation [76].
Moreover, in the T cell-transfer and DSS-induced models
of colitis, TREM-1 KO mice displayed a significantly at-
tenuated disease, associated with reduced inflammatory
infiltrates and diminished expression of pro-inflammatory
cytokines [46].
In addition to these findings, soluble TREM-1 (sTREM-1)
have been quantified in patients with IBD with the aim
at establishing whether its serum levels could serve as
surrogate marker of disease activity [77]. Both sTREM-1
and tissue TREM-1 mRNA were evaluated in patients
with CD and UC enrolled in the Swiss IBD cohort study
[77]. TREM-1 was significantly more expressed in gut tis-
sues from patients with active disease whereas sTREM-1
was similarly elevated in patients with either active or in-
active disease, although its levels were globally increased
in patients compared with healthy controls. Studies in
mice with colitis complemented these findings by showing
that gut levels of TREM-1 mRNA directly correlated with
disease activity, with increased sTREM-1 levels further
measured in mice with more controllable disease. Other
reports also documented an increase of sTREM-1 in pa-
tients with IBD, in close correlation with TNF-α and with
disease activity, especially in patients with UC [78,79]. In
particular, a total of 31 patients with UC and 22 patients
with CD were evaluated for sTREM-1 levels. Mean
sTREM-1 levels were significantly higher in IBD patients
than in healthy controls [78]. Moreover, in UC patients
Figure 3 TREM-1 and TREM-2 role in IBD. TREM-1 and TREM-2 exert similar activities in the gut microenvironment leading to the amplification
of intestinal inflammation. (A), TREM-1 is expressed on the macrophage surface of IBD patients leading to the increased production of TNF-α, IL-6,
IL-8 and MCP-1. (B), TREM-2 is expressed on the surface of mature DC exclusively in the inflamed mucosa. Increased expression of TREM-2 drives
the production of pro-inflammatory cytokines, such as TNF-α, IL-6, IL-1β and IL-12p70, and induces T-cell activation. (C), It’s still unknown if in the
inflamed mucosa of IBD patients, TREM-1 positive macrophages possess different phagocytic or killing activity, or if they displayed a peculiar
polarization. Similarly, it's not known if the pathogenic role of TREM-2 positive DCs could be mediated by selective interaction with specific TLR.
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ity was much more robust than other parameters, such as
erythrocyte sedimentation and or C-reactive protein [78].
Soluble TREM-1 has also been correlated with the occur-
rence of endoscopic markers of disease activity in a cohort
of 58 patients comprising 19 healthy volunteers, 8 patients
with CD and 31 with UC [80]. In this study sTREM-1
levels correlated with disease activity in CD patients, and
with clinical and endoscopic disease activity index of ul-
cerative colitis patients [78,79].
Finally, it has been proposed that TREM-1 genetic
polymorphisms may correlate with IBD development.Three TREM-1 single nucleotide polymorphisms (SNPs,
rs2234237, rs3789205, and rs9471535) were recently
evaluated in 202 Korean patients with CD, 265 with UC,
138 with intestinal Behcet’s disease (BD), and 234
healthy controls [80]. While TREM-1 SNPs were associ-
ated with the development of BD, no significant correl-
ation was found within IBD patients [80].
The controversial role of TREM-2 in IBD pathogenesis
TREM-2 genetic variation has been recently correlated
with Alzheimer’ disease (AD) [81]. However, it is still
unclear how TREM-2 participates in AD pathogenesis,
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avenue [82]. Despite the evidence pointing to TREM-2
as an anti-inflammatory receptor, especially in the CNS,
studies regarding its role in the intestine have yielded di-
verging results. In a model of mucosal wound healing,
TREM-2 was required for efficient mucosal repair [36].
In fact, TREM-2+ infiltrating macrophages showed an
increased expression of IL-4 and IL-13, required to
properly restore epithelial wounds. Interestingly, TREM-
2 KO mice displayed slow and incomplete wound heal-
ing accompanied with reduced epithelial proliferation
and increased infiltrate of M1 macrophages [36]. Differ-
ent results were obtained when the role of TREM-2
was addressed during IBD pathogenesis. In our study,
TREM-2 was virtually absent from colon samples of
control patients, but its levels were significantly higher
in the inflamed mucosa of patients with IBD, where
TREM-2 is mainly expressed by CD11c+ DCs [51]
(Figure 3B). In line with this data, we found that TREM-
2 genetic deletion led to a reduced susceptibility to
experimental colitis. Similarly, mucosal levels of TREM-
2 increased as acute or chronic colitis was induced in
mice and furthermore, TREM-2 KO mice developed less
severe colitis than wild-type mice, with a significantly
lower decrease in body weight, lower disease activity
index, and smaller mucosal lesions at endoscopic ana-
lysis. We also investigated colon DCs phenotypically and
functionally, providing evidence that, in the absence of
TREM-2, DCs produced lower levels of inflammatory
cytokines, had reduced levels of bacterial killing and
were defective in inducing T-cell activation in compari-
son with DCs from wild-type mice [51].
These findings highlight that even if TREM-2 possess
an important role in microglia activation in the CNS, its
role in the establishment of IBD remains controversial
and, similarly to TREM-1, suggest that targeting TREM-
2 locally in the intestine could be beneficial to treat IBD.
As for TREM-1, further studies are needed in order to
evaluate the mechanisms of regulation of TREM-2 in in-
testinal DCs as well as to identify a possible cross-talk
with TLRs.
TREM-1 and TREM-2 in IBD: what we do not know
Despite emerging evidence and preclinical studies to
date clearly supporting TREM-1 and TREM-2 as good
candidates for therapeutic intervention, no clinical stud-
ies have yet been run with IBD patients.
As discussed above, observational studies correlated
sTREM-1 levels with TNF levels in UC patients [78,79],
but sTREM-1 may have limited use as a disease bio-
marker, since there appears to be no difference in
sTREM-1 levels when comparing active and inactive dis-
ease [77]. It is therefore necessary to better define the
molecular mechanisms of TREM-1 activities during IBDpathogenesis. A functional characterization of TREM-1
expressing macrophages is therefore needed in order to
clarify whether they posses a peculiar polarization or
whether they have an impaired capacity to control bac-
terial invasion (Figure 3C). Moreover, the relevance of
other bacterial sensors, such as PRRs and, in particular,
TLRs is still unknown.
Similarly, TREM-2 activity during IBD pathogenesis re-
quires more extensive investigation. The finding that
TREM-2+ DCs possess a pro-inflammatory phenotype
does not apparently explain the increased percentage of
this specific cell type in IBD patients. Similarly to TREM-1,
the relevance of TLR activities is still unknown, even if it
has been clarified that TREM-2 augments the production
of pro-inflammatory cytokines after TLR engagement in
the intestinal microenvironment [51]. Moreover, it will be
essential to understand how TREM-2 DCs influence T- cell
activation and proliferation (Figure 3C). Interestingly,
while genetic models have been employed to analyze
the role of both TREM-1 and TREM-2 in experimental
IBD pathogenesis, the question whether genetic dele-
tion of TREM-1 or TREM-2 alters the expression of the
cognate receptor in the intestinal microenvironment
had not yet been addressed.
Conclusion
Myeloid cell function is closely controlled by members
of the TREM family. While TREM-1 plays a role in the
amplification of host inflammatory responses, TREM-2
may counterbalance the effects of TREM-1, being more
broadly implicated in the regulation of bone physiology
and microglia cell functions. The interactions between
TREM receptors and the local microenvironment are
therefore crucial to determine the outcome of an inflam-
matory response. A thorough characterization of the
intracellular signaling pathways activated by TREM-1
and TREM-2 and the identification of cooperative inter-
actions between TREM-1 and TREM-2 will allow for a
better understanding of the role of these receptors in in-
flammatory disorders.
Recent advances regarding the peculiar role of TREM-1
and TREM-2 in modulating intestinal inflammation
reinforce the opportunity to control their functions as a
novel therapeutic approach. In particular, the administra-
tion of LP17 peptide showed promising results, especially
related to the local inhibition of TREM-1 function in the
intestine. Similarly, the recent association between in-
creased mucosal levels of TREM-2 and IBD opens new ave-
nues for clinical research. TREM-2 may also be implicated
in the modulation of bacterial killing by DC, further defin-
ing TREM proteins as versatile modifiers of disease.
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